Insilico Medicine, a clinical-stage company pioneering generative AI-driven drug discovery, has announced a new research collaboration with Eli Lilly and Company to jointly develop innovative therapies.
The partnership will combine Insilico’s Pharma.AI platform with Lilly’s disease expertise to identify and optimize novel drug candidates. Under the agreement, Insilico will design and refine compounds for targets defined by Lilly, with potential payments exceeding $100 million, including upfront, milestone, and tiered royalty payments upon commercialization.
“We are delighted to collaborate with Lilly, a global leader in medical innovation,” said Alex Zhavoronkov, PhD, Founder and Co-CEO of Insilico Medicine. “This partnership validates our AI-driven discovery capabilities and strengthens our shared commitment to accelerating transformative therapies for patients worldwide.”
The collaboration builds on a 2023 software licensing agreement between the two companies and underscores Insilico’s growing influence in AI-enabled drug development. Using its proprietary AI and automation technologies, Insilico has reduced early-stage discovery timelines from several years to as little as 12 to 18 months per program.